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Abstract
Glucocorticoid (GC) induced osteoporosis (GIO) is caused by the long-term use of GC for treatment of autoimmune and
inflammatory diseases. The GC related disruption of bone marrow microcirculation and increased adipogenesis contribute
to GIO development. However, neither currently available anti-osteoporosis agent is completely addressed to
microcirculation and bone marrow adipogenesis. Salvianolic acid B (Sal B) is a polyphenolic compound from a Chinese
herbal medicine, Salvia miltiorrhiza Bunge. The aim of this study was to determine the effects of Sal B on osteoblast bone
formation, angiogenesis and adipogenesis-associated GIO by performing marrow adipogenesis and microcirculation
dilation and bone histomorphometry analyses. (1) In vivo study: Bone loss in GC treated rats was confirmed by significantly
decreased BMD, bone strength, cancellous bone mass and architecture, osteoblast distribution, bone formation, marrow
microvessel density and diameter along with down-regulation of marrow BMPs expression and increased adipogenesis.
Daily treatment with Sal B (40 mg/kg/d) for 12 weeks in GC male rats prevented GC-induced cancellous bone loss and
increased adipogenesis while increasing cancellous bone formation rate with improved local microcirculation by capillary
dilation. Treatment with Sal B at a higher dose (80 mg/kg/d) not only prevented GC-induced osteopenia, but also increased
cancellous bone mass and thickness, associated with increase of marrow BMPs expression, inhibited adipogenesis and
further increased microvessel diameters. (2) In vitro study: In concentration from 10
26 mol/L to 10
27 mol/L, Sal B stimulated
bone marrow stromal cell (MSC) differentiation to osteoblast and increased osteoblast activities, decreased GC associated
adipogenic differentiation by down-regulation of PPARc mRNA expression, increased Runx2 mRNA expression without
osteoblast inducement, and, furthermore, Sal B decreased Dickkopf-1 and increased b-catenin mRNA expression with or
without adipocyte inducement in MSC. We conclude that Sal B prevented bone loss in GC-treated rats through stimulation
of osteogenesis, bone marrow angiogenesis and inhibition of adipogenesis.
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Introduction
Glucocorticoid (GC) therapy is commonly used for inflammatory
and autoimmune diseases. The long-term administration of GC can
lead to glucorcoticoid-induced osteoporosis (GIO), which signifi-
cantly increases the patients’ morbidity and mortality. Due to
limited treatment options, the side effects of GC often have to be
tolerated during treatment [1]. Currently, the clinical management
of GIO relies on medications similar to those used for treatment of
post-menopausal osteoporosis, such as calcium, vitamin D,
bisphosphonates, raloxifene, PTH, hormone replacement and
calcitonin. These drugs do not address the multi-factor driven
GIO. In particular, they do not target the detrimental effect of GC
on bone marrow fat metabolism and circulatory system [2–5]. Thus
more studies on these GC induced effects may lead to development
of a novel therapeutic approach to prevent and treat GIO.
The pathogenesis of GIO involves multiple factors, of which
some suggest the decrease in number and functions of osteoblasts
is the main contributing factor [2]. However, recently increased
apoptosis of osteoblasts, osteocytes and endothelial cells, suppres-
sion of osteoblasts and osteoclasts, and endothelial cell precursor
production as well as prolongation of the life span of osteoclasts
have all been shown to contribute to the skeletal side effects of GC
[4–6]. Recent studies suggested that the regulation of marrow
stromal cell (MSC) differentiation into bone or fat cells [3] and the
inhibition of bone marrow microvasculature play a very important
role in GIO development [4,5]. GC can inhibit osteoblast
production of bone morphogenetic protein 2 (BMP-2), which
causes decreased MSC differentiation into bone cells [7]. GC also
directly induce differentiation of marrow stromal cells into
adipocytes and inhibit osteogenic differentiation [8]. Kitajima
et al. showed that mature fat cells exposed to high dose of GC were
larger than control cells derived from bone marrow [9]. The latter
would lead to narrowing and obstruction of capillaries in bone
marrow microvasculature from increased adipose tissue that
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flows [5,10]. Excessive GC treatment was also found to inhibit the
growth of vascular endothelial cells that further contributes to
microcirculation disturbance [11]. Marx et al. have previously
demonstrated that the peroxisome proliferator-activated receptor
c (PPARc) can induce apoptosis in vascular endothelial cells via
caspase-3 activation, thus inhibiting vascular endothelial cell
proliferation and angiogenesis [12]. GC can activate PPARc in
MSCs through different pathways to promote adipogenesis, which
reduces osteoblast differentiation, and eventually leads to fat tissue
accumulation in bone marrow [6]. Taken together, these studies
suggest that the GIO bone loss is comprised of multiple mechanisms
involving the increase in bone marrow adipogenesis and decrease in
marrow angiogenesis leading to a decrease in bone marrow
microvasculature and consequent decrease in osteogenesis [4,5].
Salvia miltiorrhiza Bunge is a traditional Chinese medicine, called
danshen, widely used in clinical practice for the prevention and
treatment of cardio-cerebral vascular diseases. Pharmacological
testing showed that danshen has anticoagulant, vasodilatory,
increased blood flow, anti-inflammatory, free radical scavenging,
mitochondrial protective and other activities [13]. Salvianolic acid B
(Sal B), the aqueous bioactive component from Salvia miltiorrhiza
Bunge, is a polyphenolic compound found in abundance in this plant.
The structure of Sal B is shown in Figure 1 which consists of three
molecules of Tanshinol, or called danshensu (D (+) b-3,4-
dihydroxyphenyl lactic acid) and a molecule of caffeic acid, Sal B
can be converted in vivo to Tanshinol (Salvianolic acid A, or Sal A),
another water-soluble bioactive ingredient of Salvia miltiorrhiza Bunge,
with similar function to Sal B. Both Sal B and Tanshinol are well-
known as among the most effective natural product antioxidants
[13,14].
Multiple pharmacological studies have found that Sal B can
attenuate the effect of myocardial ischemia-reperfusion injury
[15]. Interestingly, Sal B can also increase angiogenesis and reduce
myocardial ischemia via vascular endothelial growth factor (VEGF)
activation [16]. It also relieves brain injury by reducing neuronal
damages in cerebral ischemia [17]. Sal B can improve cellular
hypoxia-ischemia by expanding micro-arteries, improving micro-
circulation and increasing the blood flow velocity. Its beneficial
effects on blood vessel dilation and protection are believed to be
mediated by blocking calcium channels and angiotensin-converting
enzyme [18,19]. Moreover, Salvia miltiorrhiza Bunge and its aqueous
extract can increase the activity of superoxide dismutase, scavenge
Figure 1. Structure of Salvianolic acid B and Tanshinol. Salvianolic acid B consists of three molecules of Tanshinol (D (+) b-3,4-dihydroxyphenyl
lactic acid, danshensu) and a molecule of caffeic acid. Sal B can be converted in vivo to Tanshinol, another water-soluble bioactive ingredient of Salvia
miltiorrhiza Bunge, with similar function to Sal B.
doi:10.1371/journal.pone.0034647.g001
Table 1. Experimental Design.
Groups Code
Description for Treatment
and Dosage
(I) Basal control BAS Scarified at 0 day of the study
(II) Age control CON Vehicle treatment of distilled
water at 5 ml/kg/d
(III) Intact+low dose Sal B B40 Sal B treatment at 40 mg/kg/d
(IV) Prednisone model GC Prednisone acetate (Pred) at
3.5 mg/kg/d
(V) GC+low dose of Sal B GC+B40 Pred at 3.5 mg/kg/d and Sal B at
40 mg/kg/d
(VI) GC+high dose of Sal B GC+B80 Pred at 3.5 mg/kg/d and Sal B at
80 mg/kg/d
doi:10.1371/journal.pone.0034647.t001
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ROS to the vascular endothelium. Thus, Sal B functions as a
vasodilator, maintains red bloodcell deformability and increases the
function of the hematopoietic system [20]. Recently, our in vitro
studies have demonstrated that Sal A can inhibit glucocorticoid–
induced bone marrow stromal cells adipogenesis, promote osteo-
blast differentiation, bone matrix formation and bone mineraliza-
tion [21]. Therefore, we hypothesize that the clinical use of Sal B
will hold promise for a more effective and safe treatment for GIO.
The aim of the current study is to validate our hypothesis in a GIO
rat model and additional study on in vitro.
Materials and Methods
Animals
Ethical Treatment of Animals: This study was carried out in
strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of Guangdong Laboratory
Animal Monitoring Institute under by National Laboratory
Animal Monitoring Institute of China. The experiments have
been conducted according to protocols approved for Specific
Pathogen Free animal care of Animal Center of Guangdong
Medical College, and approved by the Academic Committee on
the Ethics of Animal Experiments of the Guangdong Medical
College, Zhanjiang, P.R. China, Permit Number: SYXK
(GUANGDONG) 2008-0007. All surgery was performed under
sodium pentobarbital anesthesia.
The Sprague-Dawley male rats were acclimated to local
vivarium conditions (temperature 24–26uC, humidity 67%) and
allowed free access to water and diets containing 1.33% calcium,
0.95% phosphorus, and vitamin D3 60 IU %. All rats received
subcutaneous injection of tetracycline (20 mg/kg, Sigma Chemical
Co. St. Louis, MO) on days 13 and 14, and calcein (10 mg/kg,
Sigma Chemical Co. St. Louis, MO) on 3 and 4 days before
sacrifice.
Experimental Protocols
Forty-six 6-month-old male Sprague-Dawley rats weighing
390625 grams, were randomly divided into 6 groups with 8 rats
per group, except 6 for the basal control group (Table 1). The
groups were: 1) a basal (BAS), an age control (distilled water,
CON), 3) 40 mg Sal B/kg/d (B40), 4) 3.5 mg prednisone acetate/
kg/d (GC), 5) GC+40 mg Sal B/kg/d (GC+B40) and 6)
GC+80 mg Sal B/kg/d (GC+B80). Prednisone acetate was
obtained from Guangdong Xianju Pharmacy Co. China and the
Sal B prepared as described in below. All treatments were by daily
oral gavage for 12 weeks.
Salvianolic acid B (Sal B) Preparation
The original herbal medicine Radix Salviae miltiorrhiza was
selected according to the standard protocol of the pharmacopoeia
of the People’s Republic of China [22]. The aqueous bioactive
component from Radix Salviae miltiorrhizae was extracted as
previously reported [23]. Salvianolic acid B (Sal B) and Tanshinol
found in the aqueous extract of Radix Salviae miltiorrhizae were
Figure 2. The HPLC analysis of control compounds (A) and
aqueous extraction sample (B) showing the retention time of
Tanshinol –Na (1) and Salvianolic acid B (2).
doi:10.1371/journal.pone.0034647.g002
Table 2. Primer sequences used in RT-PCR.
Gene Primer sequence
Products
Length (bp)
Runx2 59-ACTGAAGAGGCTGTTTGACG-39 (sense) 122
59-TCACTACCAGCCACCGAGA-39 (antisense)
PPARc 59-GCCTTGCTGTGGGGATGTCT-39 (sense) 240
59-CGAAACTGGCACCCTTGAAAAAT-39 (antisense)
Dickkopf-1 59-GCCTCCGATCATCAGACGGT-39 (sense) 224
59-GCAGGTGTGGAGCCTAGAAG-39 (antisense)
b-catenin 59-TGCAGCGACTAAGCAGGA-39 (sense) 198
59-TCACCAGCACGAAGGACA-39 (antisense)
GAPDH 59-ACCACAGTCCATGCCATCAC-39 (sense) 451
59-TCCACCACCCTGTTGCTGTA-39 (antisense)
doi:10.1371/journal.pone.0034647.t002
Table 3. Primer sequences used in RT-PCR.
Gene Primer sequence
Products
Length (bp)
BMP-2 59-AAATTATAAAGCCTGCCACAG-39 (sense) 326
59-TTGACGCTTTTCTCGTTTGTG-39 (antisense)
BMP-7 59-AGACGCCAAAGAACCAAGAG-39 (sense) 323
59-GCTGTCGTCGAAGTAGAGGA-39 (antisense)
GAPDH 59-CCATGGAGAAGGCTGGGG-39 (sense) 195
59-CAAAGTTGTCATGGATGACC-39 (antisense)
doi:10.1371/journal.pone.0034647.t003
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Groups Maximum force Fracture Force Elastic Force Maximum Stiffness coefficient
(N) (N) (N) deflection (mm) (N/mm)
BAS 162.93613.36** 134.58622.16** 94.99613.74** 0.9760.19 531.09649.67
CON 207.91613.01 178.77630.39 126.97624.39 0.9060.10 617.97695.61
B40 208.52621.50
gg 171.37638.07 121.35638.26 0.9060.17 678.24651.53
gg
GC 184.76617.72*
g 177.97617.86
gg 127.21619.45
gg 0.7060.11*
g 601.12678.48
GC+B40 213.40612.82
# gg 191.98621.22
gg 131.75610.85
gg 0.9460.14
# 774.13675.89
#*
gg
GC+B80 218.68615.32
##gg 184.52630.08
gg 136.11626.49
gg 0.9360.13
# 738.87657.53
#*
gg
Note: Value are mean 6 SD,
*P,0.05,
**P,0.01 vs CON;
#P,0.05,
## P,0.01 vs GC,
+P,0.05,
++P,0.01 vs GC+B40,
gP,0.05,
ggP,0.01 vs BAS.
doi:10.1371/journal.pone.0034647.t005
Table 6. Effects of Sal B, GC, and GC+ Sal B on proximal tibial metaphysis bone structure histomorphometry, osteoblast and
osteoclast contents.
Parameters BAS CON B40 GC GC+B40 GC+B80
BV/TV (%) 16.3463.52 13.1863.87 13.4463.09 9.4263.34*
gg 14.0462.56
## 17.5863.20
## *+
Tb.Th (mm) 59.5264.53 59.7768.86 59.8066.92 49.0969.11**
g 59.3666.19
# 69.8268.85
## *+
g
Tb.N (mm
21) 2.7260.43 2.1860.43 2.2560.43 1.8760.38
gg 2.3760.31
# 2.5160.25
##
Tb.Sp (mm) 316.2668.6 416.36103.1 399.02693.3 505.36123.5
gg 369.51651.3
## 332.4647.7
##
OcS/BS (%) 0.7460.33 0.6560.28 0.4760.16
g 0.8660.36 0.7960.31 0.5560.30
ObS/BS (%) 1.2160.33 1.2160.42 1.5060.68 0.3160.13**
gg 0.8060.31
# 1.0160.36
##
Note: Value are mean 6 SD,
*P,0.05,
**P,0.01 vs CON;
#P,0.05,
## P,0.01 vs GC,
+P,0.05,
++P,0.01 vs GC+B40,
gP,0.05,
ggP,0.01 vs BAS.
doi:10.1371/journal.pone.0034647.t006
Table 4. Effects of Sal B, GC and GC+Sal B on the soft tissue weights (g/1000 g body weight).
Groups Thymus Liver Adrenal gland (/100 g) Testicles Soleus
CON 0.5360.06 26.4561.28 0.9060.10 4.1760.29 0.4660.04
B40 0.5260.06 27.1361.52 0.8760.19 4.1960.27 0.4760.03
GC 0.4060.07** 28.9861.30** 0.7260.19* 4.1260.36 0.4260.02*
GC+B40 0.4860.08 28.3362.86 0.8960.12
# 4.1060.07 0.4860.06
#
GC+B80 0.4360.09* 26.9761.96
# 0.9060.17 4.1160.26 0.4760.04
##
Note: Value are mean 6 SD,
*P,0.05,
**P,0.01 vs CON;
#P,0.05,
## P,0.01 vs GC.
+P,0.05,
++P,0.01 vs GC+B40.
Not available for BSA.
doi:10.1371/journal.pone.0034647.t004
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Chinese Biological Appraisal Institute, Beijing, China (.99.0%)
[24]. HPLC chromatograms of the control compounds and
aqueous extraction samples are shown in Figure 2. The content of
Sal B was 25 mg per gram of Radix Salviae miltiorrhiza.
Body weight and serum markers assay
Rats were weighed every week. At the end of the experiments,
rats were sacrificed by cardiac puncture under anesthesia. Soft
tissues were removed and weighed. Blood and serum samples were
collected for measurements of serum calcium (Ca), the serum bone
biomarkers alkaline phosphatase (ALP) and tartrate-resistant acid
phosphatase-5b (TRACP-5b) according to manufacturers’ instruc-
tions (Immunodiagnostic Systems Inc, USA).
Immunohistochemical analysis of bone tissues
The distal femoral bone marrow cavity was exposed to prepare
decalcified bone slides. Samples were decalcified at room
temperature in 15% EDTA for 5 weeks. After decalcification,
the sample was placed in 70% alcohol and paraffin embedded.
Four micrometer paraffin slides were prepared on glass slides
coated with egg white-glycerol, or polylysine, then dried for one
hour at 60uC and stored at 4uC for future use.
Immunohistochemical analysis of bone marrow microcirculation
factor VIII-related antigen (Von Willbrand Factor, vWF) and
peroxisome proliferator-activated receptor c (PPARc) were per-
formed following the manufacturers’ instructions. Rabbit anti-
human vWF polyclonal antibody was purchased from CHEMI-
CON International, Inc, USA, and PPARc mouse monoclonal
antibody was purchased from Santa Cruz Biotechnology, Inc, USA.
Briefly, the endogenous peroxidase activity of slides wereblocked by
3% hydrogen peroxide and nonspecific binding was blocked with
10% goat serum. The slides were then incubated with primary
antibody at 4uC overnight in a humidified chamber. The next day
the slides were incubated with biotinylated secondary antibody for
15 min, washed again with PBS (2 min63 times), then incubated
with streptavidin conjugated to horseradish-peroxidase for 15 min.
After a final PBS wash (5 min63 times), a drop of freshly prepared
Table 8. Effects of Sal B, GC, and GC+ Sal B on distal femoral metaphyseal bone marrow.
Parameters BAS CON B40 GC GC+B40 GC+B80
F.Ar/TV (%) 10.6763.61 17.6766.9 11.1362.84 39.5967.15**
g 19.6765.71
##g 21.2364.53
# g
PPARc (A) 0.1860.05
## 0.2160.03 0.1860.04 0.3160.05**
gg 0.2360.03
# g 0.2060.03
##
DMV (mm) 9.7462.92* 15.0365.21 17.1864.02
gg 6.1161.64**
g 20.68610.25
##g 21.2366.86
##*
g
MVD (vWF#/view) 24.761.64 26.161.61 27.061.56 20.163.68* 25.461.63
# 27.962.57
##g
Note: Value are mean 6 SD,
*P,0.05,
**P,0.01 vs CON;
#P,0.05,
## P,0.01 vs GC,
+P,0.05,
++P,0.01 vs GC+B40,
gP,0.05,
ggP,0.01 vs BAS;
A: absorbance; vWF: positive staining of Von Willbrand Factor in the endothelial cells.
doi:10.1371/journal.pone.0034647.t008
Table 7. Effects of Sal B, GC, and GC+ Sal B on proximal tibial metaphysis cancellou bone dynamic parameters.
Parameters BAS CON B40 GC GC+B40 GC+B80
LGR (mm/d) 8.3160.45** 5.1360.43 5.3660.52
gg 4.0360.51**
gg 5.1060.25
## gg 5.3260.42
##gg
MS (%) 23.1162.92** 17.3162.62 20.7862.68*
g 17.2061.53
gg 19.7661.55
# *
g 18.4060.99
g
MAR (mm/d) 1.2360.08 1.1860.13 1.1760.09 1.0860.11*
gg 1.2160.07
# 1.2160.10
#
BFR/BS (mm/d*100) 28.4064.32* 20.4963.93 24.4064.08*
g 18.6863.41
gg 23.9562.86
## g 22.2162.06
g
BFR/BV (%/year) 291.5643.7** 214.5657.3 251.0649.0 238.8668.7
g 247.1632.3 198.8622.2
##+
g
BFR/TV (%/year) 47.02610.1** 26.5364.13 32.8764.94*
g 21.1964.97*
gg 34.2363.59
## *
g 34.3964.46
## **
g
Ec-MS (%) 84.95610.7** 62.7466.89 64.63611.16
gg 30.9465.17**
gg 50.9569.55
##gg 59.0869.88
##gg
Ec-MAR(mm/d) 3.5560.75** 1.8260.16 2.0060.22
gg 1.1660.13**
gg 1.5960.25
#gg 1.4860.37
gg
Ec-BFR/BS (mm/d*100) 298.7661.3** 114.3615.7 130.6632.3
gg 36.168.4**
gg 79.5611.3
## *
gg 89.1632.9
##gg
Note: Value are mean 6 SD,
*P,0.05,
**P,0.01 vs CON;
#P,0.05,
## P,0.01 vs GC,
+P,0.05,
++P,0.01 vs GC+B40,
gP,0.05,
ggP,0.01 vs BAS.
doi:10.1371/journal.pone.0034647.t007
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was stopped when a uniform brown color became visible on the
slide by rinsing in running water. Counterstaining was done with
hematoxylin for 5–10 seconds. A control experiment was per-
formedbyreplacingprimaryantibodywithPBS.Thismethodwasa
modification at the manufacturers’ instructions.
The evaluation of Von Willbrand Factor expression and
marrow microvessel density (MVD) were determined by counting
the number of endothelial cells showing positive staining Von
Willbrand Factor, and the MVD was determined by the total
number of vWF stained cells divided by the measured area in
previous studies [25,26]. The diameter of marrow microvessels
(DMV) was determined as the average diameters of microvessels in
the same area used to measure MVD, using a digitizing image
analysis system (Osteometrics, Inc. Decatur, GA, USA) To
evaluate PPARc positive expression in distal femur, the slides
were scanned by LeicaQ550CW image analyzer and the average
of absorbance from 30 positive expression cells on each slide was
presented as mean 6 SD (absorbance/30cells). Immunohisto-
chemical analysis of bone marrow BMP-2 and BMP-7 expressions
were performed following the manufacturers’ instructions: Antigen
retrieval was performed by high temperature and pressure
treatment of the sections in citrate buffer (0.01 mol/L, pH 6.0).
After a wash in PBS, sections were incubated with hydrogen
Table 9. Percentage change of all parameters from basal (BAS), vehicle control (CON) and predisone (GC).
%Change Aging B40 GC B40+GC B80+GC
v.s.
BAS
v.s.
BAS
vs.
CON
v.s.
BAS
v.s.
CON
v.s.
BAS
v.s.
CON
v.s.
GC
v.s.
BAS
v.s.
CON
v.s.
GC
v.s.
B40+GC
BW 12 210 8
Thymus // /225 / / 219
Liver // /1 0 / / 27
Adrenal Gland // /220 / 24 /
Testicles // / / /
Soleus // /29/ 1 4 / 1 2
Calcium // /7/ 25/ 27
TRACP-5b // /4 2 / 220 / 220
ALP // /252 / 46 / 104 40
PF-BMD 222 220 19 29 8
Whole Femur BMD 28 215 211 22 10
Max force 28 28 13 211 31 16 34 18
Fracture Force 33 (27) 32 43 37
Elastic Force 34 (28) 34 39 43
Max Deflection 228 222 34 33
Stiffness 28 46 25 29 39 20 23
BV/TV (219) 242 229 49 33 87 25
Tb.Wi 218 218 21 17 17 42 18
Tb.N (220) 231 27 (15) 34
Tb.Sp (32) 60 227 (220) 234
OcS/BS (214) 238 (228) (32) (22) (28) (215)
ObS/BS (24) 274 274 (234) 158 (217) 226
LGR 238 235 252 221 239 27 236 32
MS/BS 225 210 20 226 214 14 15 220
MAR 212 281 2 1 2
BFR/BS 228 214 19 234 (29) 216 28 222
BFR/BV 226 218 232 217 220
BFR/TV 244 230 24 255 220 227 29 62 227 30 62
Ec-MS/BS 226 224 264 251 240 65 230 91
Ec-MAR 249 244 267 236 255 37 258 (219) 28
Ec-BFR/BS 262 256 (14) 288 268 273 230 120 270 (222) 147
PPARy (17) (214) 72 48 28 226 235
Fat/TV (66) (4) (237) 271 124 84 250 99 246
DMV 54 76 (14) 237 259 112 (38) 238 118 41 247
MVD (vWF#/view) 223 26 13 39
Note: This table shows significant %change from BAS, CON and GC, respectively. ( ): useful non-significant %changes. /: not available.
doi:10.1371/journal.pone.0034647.t009
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and then washed in PBS. The slides were incubated with Ultra V
Block for 30 min at room temperature. The primary antibodies
were incubated according to the manufacturer’s protocol (Maixin-
Bio, China). Slides with serial sections were incubated with the
primary antibodies (Santa Cluz Corporation) in a humidified
chamber at 4uC overnight, followed by being incubated with
streptavidin-perosidase avidin for 10 min at room temperature.
Diaminobenzadine (DAB) staining was done by incubating the
sections with coloring reagent. The sections were counterstained
with Harris’ haematoxylin, dehydrated through increasing con-
centrations of alcohol and mounted with coverslips. One section
on each slide was used as a control to assess nonspecific binding.
For this section, dilution buffer without antibody was used.
Bone mineral density (BMD) determination
The right femurs of the rats were wrapped with saline saturated
gauze to maintain moisture and stored at 220uC. After thawing at
room temperature, the femurs were moisturized by soaking in saline
solution, the residual muscle removed and the length of femur
measured with a ruler. The femur bone mineral density between the
midpoint and the distalend of the femurwasscanned witha SD-1000
single-photon bone mineral density instrument (Nuclear Industry
Beijing Institute of Geology) to measure the bone mineral content
(BMC, g/cm) and bone width (BW, cm). The bone mineral density
(BMD) measurements were performed at the midpoint of the femur
and 2 cm proximal and the BMD was calculated as BMC/BW.
Bone mechanical properties determination
After measuring BMD, the femur was used to determine the
bone mechanical properties through three-point bending using
Bose ElectroForce Testing system (ELF3510, Bose, USA). Bone
samples were tested with a 1 mm indenter, at speed of 0.01 mm/s
with a 15 mm span (L). Force (F) and deflection (D) that
automatically recorded. The output parameters include elastic
force (the force required to cause bone specimens to deform, N),
maximum force (the maximum force the bone can resist, N),
fracture force (the force required to cause bone fracture, N) and
the maximum deflection (maximum degree of the bone displace-
ment, mm). The stiffness coefficient (load-displacement curve
slope, N/mm) was also calculated based on the above parameters.
Bone Histomorphometry
The right proximal tibial growth plate and metaphyses were
processed for cartilaginous longitudinal growth rate and cancellous
bone histomorphometric analyses. The samples were opened to
expose the bone marrow cavity using an Isomet Low Speed Saw
(Buehler, Lake Bluff, Illinois, USA) and fixed in 10% phosphate
buffered formalin for 24 hours. They were then dehydrated in
graded ethanol, defatted in xylene, and embedded undecalcified in
methyl methacrylate [27]. Frontal sections were cut at thicknesses
of 4-and 10-mm. The 4-mm sections were stained by Goldner’s
Trichrome for static histomorphometric measurements. The 10-
mm unstained sections were used for dynamic histomorphometric
analyses [28].
A digitizing image analysis system (Osteometrics, Inc. Decatur,
GA, USA) was used for quantitative bone histomorphometric
measurements. Briefly, the regional of interest were the proximal
tibial growth plate and the proximal tibial metaphysis (PTM)
located between 1 and 4 mm distal to the growth plate-epiphyseal
junction. Static measurements included total tissue volume (TV),
trabecular bone volume (BV), marrow fatty area (F.Ar), trabecular
bone surface (BS), osteoclast surface (OcS) and osteoblast surface
(ObS). Dynamic measurements include interlabel width in the
growth plate (G-Int.Wi) of PTM, trabecular single-labeled surface
(sL.S), double labeled surface (dL.S) and interlabel width (Int.Wi),
and endocortical single-labeled surface (Ec-sL.S), double labeled
surface (Ec-dL.S) and endocortical interlabel width (Ec-Int.Wi).
These parameters were used to calculate longitudinal growth rate
(LGR), percentages of trabecular bone volume (BV/TV),
trabecular number (Tb.N), trabecular thickness (Tb.Th), trabec-
ular separation (Tb.Sp), marrow fatty area (F.Ar/TV), osteoclast
surface (OcS/BS), osteoblast surface (ObS/BS), longitudinal
growth rate (LGR), mineralizing surface (MS/BS), mineral
Figure 3. Body weight (g) changes during the experimental period. Body weight measurements from vehicle (aging) control (CON), Sal
B40 mg/kg/d alone (B40), prednisone alone (GC), GC plus 40 mg Sal B/kg/d (GC+B40) and GC plus 80 mg Sal B/kg/d (GC+B80) treated rats. Only the
GC treated rats showed a significant 10% lower body weight versus CON. Significant weight loss began at 10 weeks post treatment. *P,0.05,
** P,0.01 vs CON;
#P,0.05,
##P,0.01 vs GC.
doi:10.1371/journal.pone.0034647.g003
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bone surface (BFR/BS), bone volume (BFR/BV), and tissue
volume (BFR/TV), endocortical mineralizing surface (Ec-MS/
BS), endocortical mineral apposition rate (Ec-MAR), endocortical
bone formation rate (Ec-BFR) per unit of bone surface (Ec-BFR/
BS) as previously described [29,30].
Culture of rat osteoblast and marrow stromal cell (MSC)
Osteoblastic cell was isolated from newborn rat calvaria (rOB).
After removing the periosteum, the bones were cut into small flaps
of 1 mm
3 and subjected to digestion with 0.25% trypsin (Life
Technologies Gibco-BRL) for 20 min at 37 C. After centrifuga-
tion, supernatants were discarded to remove the fibroblast
population. Then the flaps were digestion with 0.2% collagenase
type I and 0.1% hyaluronidase (Life Technologies Gibco-BRL) for
six 20 min intervals at 37 C. The samples were then washed
thoroughly with Dulbecco’s modified eagle’s medium (DMEM,
Gibco). The precipitates and bone flaps were transferred to
25 cm
2 culture flasks and cultured in Dulbecco’s modified eagle’s
medium, 100 U/mL penicillin, 100 mg/mL streptomycin and
10% fetal bovine serum (FBS, Gibco) at 37uC in a humidified
Figure 4. Biomarker changes in the blood. Serum calcium (Ca, mg/
ml), alkaline phosphatase (ALP, KU/100 ml) and tartrate-resistant acid
phosphatase-5b (TRACP-5b, U/L) from vehicle (aging) control (CON), Sal
B40 mg/kg/d alone (B40), prednisone alone (GC), GC plus 40 mg Sal B/
kg/d (GC+B40) and GC plus 80 mg Sal B/kg/d (GC+B80) treated rats. The
GC treatment significantly increased serum calcium and TRACP-5b and
reduced ALP, while the Sal B significantly inhibited these GC induced
changes. Value are mean 6 SD, *P,0.05, ** P,0.01 vs CON;
#P,0.05,
#
#P,0.01 vs GC.
doi:10.1371/journal.pone.0034647.g004
Figure 5. Effects of different groups on Bone Mineral Density
(BMD, mg/cm). BMD measurements of proximal femur (PF) and whole
femur (WF) from vehicle (aging) control (CON), Sal B40 mg/kg/d alone
(B40), prednisone alone (GC), GC plus 40 mg Sal B/kg/d (GC+B40) and
GC plus 80 mg Sal B/kg/d (GC+B80) treated rats. GC treatment
significantly reduced BMD at both sites, while Sal B prevented this
reduction in GC treated rats. Value are mean 6 SD, *P,0.05, ** P,0.01
vs CON;
#P,0.05,
## P,0.01 vs GC.
doi:10.1371/journal.pone.0034647.g005
Figure 6. Effects of different treatments on proximal tibial
metaphyses (PTM) bone structure and trabecular mass.
Representative micrographs of PTM from basal (BAS), vehicle (aging)
control (CON), prednisone (GC) and GC plus 80 mg Sal B/kg/d (GC+B80)
treated rats. BAS: 6-month-old beginning control. CON: 9-month-old
terminal vehicle control with fewer trabeculae. GC: Prednisone induced
further reduction in cancellous bone mass and thinner trabeculae
versus CON. GC+B80: Sal B80 treated GC rats had increased cancellous
bone mass with thicker trabeculae compared to BAS and CON. (Masson-
Goldner Trichrome stain: trabecular in green stain). Quantitative
measurements of static parameters are shown in table 6.
doi:10.1371/journal.pone.0034647.g006
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medium was changed every 3 days. MTT (3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) (Bio-Rad, USA) assay was
use for the observation of cell growth/death.
Primary rat bone marrow stromal cells (rMSC) were collected
from marrow of femur in 4-week-old Wistar rats (obtained from
the Laboratory Animal Center of Guangdong Medical College)
[21]. The rMSC then were prepared by gradient centrifugation at
9006g for 30 min on a Percoll-Paque gradient (Amersham
Pharmacia, USA) at a specific gravity of 1.073 g/mL. The low-
density mononuclear cells were washed twice in Hanks’ balanced
salt soltion and cultured in DMEM supplemented with 10% FBS
and 1% antibiotic (10 000 U/mL penicillin G sodium, 10000 mg/
mL streptomycin sulfate) at 37 C in a humid atmosphere
containing 5% CO. The medium was changed every 3 to 4 d to
remove the non-adherent hematopoietic cells. The adherent cell
population was expanded and passaged every 12 to 14 d. All cells
used for the experiments have been through three passages. To
identify the abilities of rMSC with regard to osteogenesis and
adipogenesis, the following studies were performed.
Induction of osteogenic differentiation of rMSC (OB-in): When
the rMSC from passage number 2 became 80% confluent in
the culture plates, the culture medium was changed to an osteo-
blast inducing medium containing 50 mg/mL L-ascorbic acid,
10
22 mol/L b-glycerophosphate, and 10
28 mol/L dexametha-
sone. When the cells became layered and confluent up to 100%,
visible symmetric colonies were observed after osteoblast induction.
Induction of adipogenic differentiation of rMSC (Ad-in): The
rMSC of each group were replated at 26104 cells/cm
2 in a
25 cm
2 culture dish and maintained until 80% confluence. Then,
the culture medium was switched to adipogenic medium consisting
of control medium supplemented with 10 mg/ml insulin (Sigma,
St. Louis, MO), 10
25 mol/L dexamethasone (Sigma, St. Louis,
MO), 2610
24 mol/L indomethacin (Sigma, St. Louis, MO) and
5610
25 mol/L isobutylmethyl xanthine (IBMX, Sigma, St. Louis,
MO) for an additional 5 days followed by total RNA isolation.
Identification for OB-in and Ad-in of MSC had according to
the methods referred to Cui. et al. [21].
Determination of alkaline phosphatase (ALP) and
osteocalcin secretion
ALP activity assay: Cells were seeded in 96-well plates and the
confluent cells were cultured for the indicated period with or
without Sal B treatment. Cells were washed with PBS and 150 mL
of substrat buffer (6.7 mmol/L disodium p-nitrophenylphosphate
hexahydrate, 25 mmol/L diethanolamine and 1 mmol/L MgCl)
was added. After the mixtures were incubated at 37uC for 3 min,
we measured the absorbance at 405 nm.
Determination of osteocalcin secretion: Cells were seeded in 6-
well plates at a seeding density of 2610
4cells/cm
2 and were further
Figure 7. Effects of different treatments on Proximal tibial cartilage growth and mineral bone formation. Representative fluorescence
micrographs of interlabel width in the growth plate (G-Int.Wi), interlabel width in the endocortical (Ec-Int.Wi) and double labeling in trabecular
surface (Tb.dL.S) in basal (BAS), vehicle (aging) control (CON), prednisone alone (GC) and GC plus 80 mg Sal B/kg/d (GC+B80) treated rats. Arrows
point to interlabeling distances after double labeling with tetracycline and calcein. The interlabeling distance in the growth plate was used to
determine longitudinal growth rate (LGR). There were age-related decreases in LGR and in endocortical bone formation from 6 month (BAS) and 9
month (CON) and a further reduction with prednisone alone treatment (GC), while 80 mg/kg/d of Sal B (GC+80) prevented the GC-induced reduction.
There was an absence of double labeling in the trabecular surface after GC treatment, while the GC+B80 section exhibited similar double labeling to
BAS and CON rats. (Villanueva bone stain under fluorescence light). Quantitative measurements of dynamic parameters are shown in table 7.
doi:10.1371/journal.pone.0034647.g007
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the culture, the conditioned media were collected for assessment.
The concentration of free osteocalcin was measured by radioim-
munoassay (RIA) according to the manufacturer’s instructions
(Tian Jin Nine Tripods Medical& Bioengineering Co, LTD). The
intra-assay variance of the measurements of osteocalcin RIA was
1.26%.
Reverse transcription polymerase chain reaction (RT-PCR)
assay
Test of cultured cells: Total RNA was extracted from cultured
cells using TRIZOL reagent (Invitrogen, Carlsbad, CA) and
subjected to RT-PCR analysis using the 9600Gen Amp PCR
system (PerkinElmer Applied Biosystems, USA) with PCR
reagents (Invitrogen, Carlsbad, CA) according to the manufactur-
er’s protocol. Primers used are listed in Table 2. Amplified
products were then loaded on a 2% agarose gel and subjected to
electrophoresis. Digital pictures were taken and analyzed with gel
image system. Each gene expression was normalized to GAPDH.
Test of rat femur bone tissue: The upper femur halves obtained
were snap-frozen in liquid nitrogen and stored at 270uC. Total
RNA was prepared using TRIZOL reagent and stored at 220uC
in ribonuclease (RNase)-free water until use. To determine mRNA
levels, a one-step reverse transcription-polymerase chain reaction
(RT-PCR) procedure was performed using the 9600Gen Amp
PCR system (PerkinElmer Applied Biosystems, USA) according to
the manufacturer’s protocol. Primers used are listed in Table 3.
Amplified products were then loaded on a 2% agarose gel and
subjected to electrophoresis. Digital pictures were taken and
analyzed using Bandscan analysis software. Each gene expression
was normalized to GAPDH.
Statistic Analysis
Data were presented as mean6 SD. The statistical differences
among groups were evaluated using variance (ANOVA) with
Fisher’s PLSD test. Probabilities (p) less than 0.05 were considered
significant.
Results
Effect of Aging
Aging has a significant impact on the bone architecture and
microvasculature density. Compared with the 6 month old rat, the
aging associated changes seen at 9 months included significantly
increased femoral cortical bone strength parameters (i.e. the
maximum, fracture and elastic forces increased by 28, 33 and
34%), decreased proximal tibial (PT) longitudinal growth rate
(LGR) (down by 38%), decreased proximal tibial metaphyses
(PTM) cancellous bone formation (i.e. MS/BS, BFR/BS, BFR/
BV, BFR/TV down by 25, 28, 26 and 44%) and endocortical
bone formation indices (i.e. Ec-MS/BS, Ec-MAR and Ec-BFR/
BS by 26, 49 and 62%), these changes were associated with
significantly increased distal femoral marrow microvessels diam-
eter (DMV), up by 54%. No available data of soft tissue in 6
month old rat. (Tables 4–9, Figures 3–9).
There were non-significant reductions in PTM cancellous bone
mass (BV/TV down by 19%, Tb.N down by 20%, Oc.S/BS down
by 14%), and increased Tb.Sp (up by 32%). In addition, PPARc
Figure 8. Effects of different treatments on osteoblast morphology and adipocyte distribution and corresponding PPARc
expression. Representative micrographs in basal (BAS), vehicle (aging) control (CON), prednisone (GC) and GC plus 80 mg Sal B/kg/d (GC+B80)
treated cancellous bone in distal femoral metaphysic. Arrows point to osteoblasts (Ob, Goldner’s Trichrome stain). Active osteoblasts are present as
multi- plump columnar lining on the trabecular surface in BAS and CON rats. The GC treatment induced the appearance of shriveling and inactive
osteoblasts (v.s. BAS & CON) while the Sal B treatment protected GC-induced osteoblast impairment (GC+B80 v.s.GC). Adipocyte content (F.Ar,
Hematoxylin stain) and corresponding immunohistochemical staining of Peroxisome Proliferator-Activated Receptor c (PPARc) expression (arrows
from spots, PPARc stain) increased between 6 and 9 months (BAS v.s. CON). The GC treatment markedly increased adipocyte number and size (GC v.s.
BAS & CON), and the amount of PPARc positive cells, while the Sal B treatment prevented the GC-induced increases (GC+B80 v.s.GC). Quantitative
measurements of osteoblasts, fatty area and PPARc expression are shown in table 6 and table 8.
doi:10.1371/journal.pone.0034647.g008
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and 66% but did not reach significance. (Tables 6,8,9, Figures 7,8).
Effect of Sal B40 in Intact Male Rats
Sal B40 treatment in intact male rats stimulated cancellous and
endocortical bone formation. Compared to the vehicle (aging)
control, the 40 mg of Sal B/kg/d (Sal B40) treated intact male rat
showed no significant changes on body and soft tissues weights,
bone mineral density (BMD), femoral cortical bone strength, PTM
cancellous bone mass, architecture and endocortical bone
formation. However, the Sal B40 treated rats showed significant
increased select PTM cancellous bone formation indices (i.e. MS/
BS, BFR/BS and BFR/TV up by 20, 19 and 24%), increase
Ob.S/BS by 24% and Ec-BFR/BS by 14%. Additionally, the Sal
B40 non-significantly reduced distal femoral marrow PPARc
expression by 14%, reduced marrow fatty area (F.Ar/TV) by 37%
and increased DMV by 14%. (Tables 4–9; Figures 3–5,9)
Effect of GC in Intact Male Rats
GC induced losses in bone mass, BMD and mechanical strength
associated with decreased osteogenesis, angiogenesis and increased
adipogenesis. Compared to vehicle (aging) controls, the use of GC
lead to significant increased of liver weight by 9.6%, and reduction
in body, thymus, adrenal gland and soleus muscle weights by 10,
25, 20 and 9%, respectively, coupled with significantly increased
serum calcium by 7%, tartrate-resistant acid phosphatase-5b
(TRACP-5b) by 42% and decreased alkaline phosphatase (ALP)
by 52%. Proximal femur and whole femur BMDs were decreased
by 20% and 11% and cortical bone strength was reduced (i.e.
maximum force and deflection by 11% and 22%). GC further
significantly reduced PTM cancellous BV/TV by 29%, Tb.Wi by
18%, Ob.S/BS by 74%, PT LGR by 21%, and some PTM
cancellous bone formation indices (i.e. MAR and BFR/TV) by 8
and 20%, Significant reductions were seen in the endocortical bone
formation indices (i.e. Ec-MS/BS, Ec-MAR and Ec-BFR by 51, 36
and 68%), and microvessels diameter (DMV, down by 59%) and
density (MVD) down by 23%, while fatty marrow content was
increased by 124% and PPARc expression by 48% (Table 4–9,
Figure6–9).Immunohistochemicalanalysisofbone marrowBMP-2
and BMP-7 expression significant decreased with decrease of total
BMP-2 and BMP-7 mRNA expression (Figure 10).
Effect of Sal B40 in GC treated Male Rats
Sal B40 treatment of GC-treated rats prevented most of the GC-
induced changes. Compared to vehicle (aging) controls, the 40 mg Sal
B/kg/d (Sal B40) - treated GC rats showed no significant differ-
ences in terms of body and soft tissues weights, serum bone bio-
markers, BMD, biomechanical properties (except for increase in
stiffness by 25%),PT LGR, PTM cancellousbonemass,architectures,
MAR, BFR/BS, BFR/BV, Oc.S/BS and Ob.S/BS, endocortical
formation indices (i.e. Ec-MS/BS, Ec-MAR, except for a decrease in
Ec-BFR/BS by 30%), DMV and MVD, F.Ar/TV and distal femoral
marrow PPARc expression, and both mRNA and positive expression
of BMP-2 and BMP-7. (Tables 4–9; Figure 3–5, 9–10)
Furthermore there were no differences in skeletal cell and tissues
values, except for significantly increased PTM cancellous MS/BS
(up by 14%) and BFR/TV (up by 29%), and decreased Ec-BFR/
BS (down by 30%). (Tables 4–9; Figures 3–5)
The Sal B40 treated GC rats tended to exhibit a larger marrow
DMV (up by 38%) versus agingcontrol, that resulted in significantly
increased DMV by 238%, when compared to GC control. The rats
treated with Sal B40 showed reduced PTM cancellous bone Ob.S/
BS by 34%, while the GC alone was reduced by 74%. The results
suggests that both osteoblasts and microvessel diameters were
stimulated by Sal B40. (Tables 4–9; Figures 3–5,9)
Effect of Sal B80 in GC treated Male Rats
Sal B80 treatment of GC rats for 12 weeks not only prevented
GC-induced changes but also showed additionally stimulated
osteogenesis that increase cancellous bone mass and increased
marrow angiogenesis by enlargement of microvessels diameter.
Compared to vehicle (aging) control, the GC treated rats
receiving 80 mg of Sal B/kg/d (Sal B80) showed no significant
differences in body and soft tissue weights, serum biomarkers,
BMD, bone strength (except for stiffness), and marrow PPARc
expression, BMP-2 and BMP-7 expression, fatty marrow and
MVD. However, the Sal B80 treated rats significant differed from
Sal B40 treated rats in term of PTM cancellous bone mass up by
33%, Tb.Wi by 17%, BFR/TVby 30% and marrow DMV by
41% versus aging control. (Tables 4, 5, 8&9; Figures 3–9)
Compared to the Sal B40 treatment there was a significantly
dose response increase in serum ALP level by 40%, in proximal
femur BMD by 8%, in PTM cancellous BV/TV by 25%, in
Tb.Wi by 18% and significantly decrease in BFR/BV by 20%.
(Tables 4, 5, 8&9; Figures 3–9)
Figure 9. Effects of different treatments on marrow microves-
sel structures. Representative micrographs of immunohistochemical
staining of Von Willbrand Factor (vWF) in microvessel endothelial cells
of the distal femoral metaphysis from basal (BAS), aging control (CON),
Sal B alone (B40), prednisone treated (GC), GC plus Sal B40 m g/kg/d
(GC+B40) and GC plus Sal B80 mg/kg/d (GC+B80). The diameter of
microvessels but not density increased between 6 and 9 months (BAS
v.s. CON). The GC treatment markedly decreased the density and
diameter of microvessels with the appearance microvessels squeezed
by the increased adipocytes (GC v.s. BAS & CON). Sal B treatment
prevented the GC induced changes. High dose (Sal B80 mg/kg/d)
treatment significant increased the diameter of the microvessels
(double arrows) (vs. GC & CON). Quantitative measurements of
microvessel diameter (DMV) and density (MVD) are shown in table 8.
doi:10.1371/journal.pone.0034647.g009
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differentiation in vitro
When cultured different concentration of Sal B with rOB,
Sal B at concentration from 10
28 mol/L to 10
26 mol/L stimulated
rOB cell growth and proliferation, increased ALP activity and
osteocalcin secretion, this effect appeared in a time and dose-
dependent manner, when the concentration reached 10
25 mol/L
the cell death occurred with function decrease. (Figure 11).
Sal B at 5610
27 mol/L stimulated ALP secretion in MSC
which was similar to the action of osteoblast induction media (OB-
in), Sal B from 10
28 mol/L to 10
26 mol/L further increased OB-
in treated-MSC secretion of ALP and osteocalcin, which reveal the
ability of MSC differentiation into osteoblast by Sal B. (Figure 12)
Effect of Sal B on Dickkopf-1(DKK-1)/b-catenin mRNA
expression in MSC
DKK-1 is an inhibitor of Wnt signaling and GC is a strong
stimulator of DKK-1. When MSCs were exposed to adipocyte
induction medium (Ad-in, containing high concentration of GC),
PPARc mRNA expression increased accompanied with increases
of DKK-1 mRNA expression while b-catenin mRNA expression
decreased when compared to control. Treatment with 10
27 mol/
L Sal B and 5610
27 mol/L Sal A decreased PPARc and DKK-1
mRNA expression and increased b-catenin mRNA expression
with or without adipocyte inducement medium. Sal B 10
27 mol/L
and Sal A 5610
27 mol/L also increased Runx2 mRNA
expression without osteoblast inducement medium (Figure 13).
Discussion
The current study found that GC treatment decreased bone
formation by inhibiting osteoblast activity and marrow production
of BMP-2 and BMP-7, increased marrow adipocytes with elevated
PPARc expression that promoted bone marrow stromal cell
differentiation into adipocytes. Since osteoblasts and adipocytes
share common bone stromal progenitors [31], GC treatment
stimulate the differentiation of marrow stromal cells to adipocytes
thereby, reducing the pool of local progenitor cells to differentiate
into osteoblasts, The reduction in osteoblast number in turn
contributes to decreased osteogenesis. Furthermore, we specifically
labeled marrow vascular endothelial cells with Von Willbrand
Factor and observed similar GC disruption of marrow microvessels
as previously observed in rabbit femoral head [32]. The disruption
of marrow microvasculature would reduce the source of circulating
progenitor cells supporting osteogenesis [33–39]. The reduction in
local and circulating progenitors would then lead to reduce
osteogenesis. Our findings suggest that bone formation, bone
Figure 10. Effects of different treatments on BMP-2 and BMP-7 expression. A: Representative micrographs of immunohistochemical
staining of BMP-2 in femur bone marrow and trabeculae from control (CON), prednisone treated (GC), GC plus Sal B40 m g/kg/d (GC+B40) and GC
plus Sal B80 mg/kg/d (GC+B80). BMP-2 was stained as brown color with sand-like deposition along trabecular surface and marrow mesenchymal
stem cells. The GC treatment markedly decreased the BMP-2 expression while Sal B treatment prevented the GC induced changes. B: Electrophoresis
image of BMP-2 and BMP-7 mRNA expression in rat whole femur bone was determined by RT-PCR. The rats treated with GC decreased both BMP-2
and BMP-7 mRNA expression. Treatment of Sal 40 and 80 mg/kg/d completely prevented the GC induced changes, Sal 40 mg/kg/d alone did not
affect the BMP-2 and BMP-7 mRNA expression. Value are mean 6 SD, *P,0.05, ** P,0.01 vs CON;
#P,0.05,
## P,0.01 vs GC.
doi:10.1371/journal.pone.0034647.g010
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plates and cultured, then transferred to a medium containing various concentrations of vehicle and Sal B. MTT was tested at 24, 48, 72 and 96 h of
incubation (A), ALP activity (represent by OD value) was determined later until 7 days of incubation (B), and the content of osteocalcin (mg/L) in
culture medium was determined 1n day 21 after incubated with different treatment (C). Data shown are mean 6 SD. n=6. **P,0.01, *P,0.01 versus
control (vehicle treatment).
doi:10.1371/journal.pone.0034647.g011
Figure 12. Effects of Sal B on rat marrow stromal cell (rMSC) differentiation into osteoblast. Cells were collected from the femur marrow
of one month old SD rats. Cells inoculated in 25 mm
2 culture flask and cultured. The cells used in the study were the 3 passage, then transferred to
the medium containing osteoblast induction medium (OB-in), Sal B and OB-in plus various concentrations of Sal B respectively. A: ALP activity
(represent by OD value) was determined at 3, 5 and 7 days. B: the content of osteocalcin (mg/L) in culture medium was determined 1n day 21 after
incubated with different treatment. Data shown are mean 6 SD. n=6. **P,0.01, *P,0.05 versus control (vehicle treatment).
doi:10.1371/journal.pone.0034647.g012
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each other and confirm that the latter two factors also contribute
significantly to the development of GC-induced bone loss and the
decline in bone strength [4,5].
Our data found 80 mg Sal B/kg/d for 12 weeks depressed
adipogenesis and stimulated angiogenesis and osteogenesis in GC-
treated rats. The lower 40 mg Sal B/kg/d dose in GC treated rats
only depressed adipogenesis and stimulated cancellous bone
formation rate. The 40 mg dose also appeared to increase
angiogenesis by enlarging marrow microvessels diameter but the
observations were not statistically significant. The prevention of
GC-stimulation of adipogenesis maintains marrow stromal and
red marrow cell levels at control levels. Since osteogenesis and
adipogenesis share common bone stromal progenitors [31], this
means the pool of marrow progenitors available to differentiate
into osteoblasts will be maintained and not be preferentially
stimulated to form adipocytes by GC treatment. Additionally the
maintenance of red bone marrow means that the bone marrow will
retain more microvessels, unlike fatty bone marrow, which is not as
well vascularized [40,41]. The Sal B treatment further increased
marrow angiogenesis that increases blood flow to improve nutrition
and source of circulating progenitors [33–39]. In support of
osteogenesis, stimulated angiogenesis reduced intraosseous pressure
that increases blood flow and in turn stimulates osteoblastic activity
(i.e. mineral apposition rate) [42]. Further red bone marrow sites
with better vasculature exhibit a factor of 10 higher bone
remodeling and formation rates than fatty marrow bone sites [43–
46]. Also the improved blood flow increases osteocyte lacunar-
canaliculi and blood vessel fluid volume that increase bone strength
and reduce the risk of fracture [4,47].
To clarify the mechanism by which Sal B promotes osteoblast
differentiation and alleviates GC-induced impairment of bone
formation, we examined the effects of Sal B on primary rat
calvarial osteoblasts and rat bone marrow stromal cell by up-
regulating Wnt/b-catenin signaling. Our data showed that Sal B
stimulates osteoblast cell growth and MSC differentiation into
osteoblast maturation (secretion of ALP and osteocalcin) with a
dose and time dependent manner that mimicks the action of
osteoblast inducer. This study further demonstrated that Sal B
activated Runx2 and b-catenin mRNA expression and declined
DKK-1 and PPARc mRNA expression which had been induced
by GC (i.e. adipocyte inducement). It is known that canonical
Wnt/b-catenin is a key pathway for regulating bone formation
and remodeling and contributes to osteoblastic differentiation
[48], of which DKK-1 is one of the inhibitor in Wnt-signaling.
Studies demonstrate GC to be a very strong inducer of DKK-1
protein [49] which leads to a decrease in osteoblast bone
formation in GC induced osteoporosis [50]. Moreover, Runx2
was found to integrate Wnt-signaling for mediating osteogenic
differentiation of MSCs [51], it was known to be involved in BMP
signaling as mentioned earlier [52]. Our in vivo observation
further demonstrated that Sal B stimulated femur bone BMP-2
and BMP-7 mRNA expression and protected GC-treated rats
from decrease of femur bone BMP-2 and BMP-7 protein
expression (IHC revealed, Figure 10). BMP/Wnt/b-catenin share
a crossover mechanism for stimulation of progenitor, osteoblast
and angiogenetic generation [53], thus our study support the idea
that Sal B protected against GC-induced osteoblast impairment
associated abnormal angiogenesis and adipogenesis. Recently Lu
et al. reported that Sal B protected against oxidative stress–
induced apoptosis in rat bone marrow stem cells [54] suggesting
that Sal B may inhibit GC-induced bone marrow stem cell
apoptosis to enlarge the local pool of osteoblast precursors
available for osteogenesis.
Our current end point findings indicated that Sal B stimulated
bone formation in both intact and GC-treated male rats (Table 9).
Sal B40 alone in intact male rats significantly increased BFR/TV by
24%, Sal B 40 in GC-treated rats significantly increased BFR/TV
by 29%, while Sal B80 in GC-treated rats significantly increased
BFR/TV by 50% and additionally increased cancellous bone mass
(BV/TV) by 33% and trabecular thickness by 17%. Taken together,
the combination of improved marrow microenvironment (i.e.
increasedlocalandcirculatoryprogenitors,bloodflowandnutrition)
andSal B stimulation of bone formation rate not only prevented GC
- induced osteopenia but also increased cancellous bone mass.
The current study used doses of 40 and 80 mg/kg gavage in
rats, which is similar to the dose used in humans. Salvianolic
Acid B (parental form) was approved by the State Food and Drug
Administration (SFDA) of China in 2007 for clinical use in the
prevention and treatment of cardiovascular diseases. The
recommended dose of Salvianolic Acid B for humans is 4 mg/
kg/d i.v. Our study examined the drug impact on body weight
(Figure 3), organ weight (table 4), gross necropsy and histopathol-
ogy (negative data not shown) both in intact rats (SalB40 group)
and glucocorticoid-treated rats. No significant adverse effects on
these parameters were observed. Recently Li et al. [55] reported
on the toxicity of Sal A, a derivative of Sal B, in male and female
dogs after a 3-month continuous intravenous infusion at doses
of 17, 50, and 150 mg/kg/day. No significant cumulative toxicity
was observed either during or 90 days following treatment.
Importantly, the doses of Sal A used in dogs were very high as
compared to clinical practice and to rats; the 17, 50, and 150 mg/
kg/day in dogs are equivalent to 61.2, 180 and 540 mg/kg in rats.
Sal B possesses a similar activity to Sal A. Our data indicate that
the doses of Sal B used in current study are safe and effective and
produce no adverse effects.
In summary, Sal B treatment of GC-treated male rats not only
prevented GC-induced osteopenia but also increased cancellous
bone mass by the combination of depressed adipogenesis and
stimulated angiogenesis and osteogenesis (Figure S1). Our findings
support further investigation of Sal B stimulating of osteogenesis
and marrow circulation and inhibition of adipogenesis as a
potential therapeutic strategy in the prevention of not only GC-
induced osteopenia but other bone diseases.
Supporting Information
Figure S1 Working scheme: the mechanism of action of
Salvianolic acid B on glucocorticoid induced bone loss.
Decrease of osteogenesis and angiogenesis, increase of adipogen-
esis are considered contributions to glucocorticoid induced bone
loss. Salvianolic acid B could withstand the impairment induced
by glucocorticoid. (BMPs: bone morphogenetic proteins; MSCs:
Figure 13. Effects of Sal B on the gene expression of Dkk-1/b-catenin pathway in rat marrow stromal cell (rMSC) differentiation.
rMSC were cultured with osteoblast induction medium (OB-in), adipocyte induction medium (Ad-in, i.e. high concentration of GC), with or without Sal
B (10-7 mol/L) and Sal A (5610-7 mol/L, a derivant of Sal B, Figure 1) for 7 days. Expression levels of Runx2 (A) , PPARc (B), b-catenin (C and D) and
DKK-1 (E) were measured by RT-PCR. Sal B increased Runx2 and b-catenin mRNA expression and decreased DKK-1 mRNA expression which was similar
to the action of OB-in. Ad-in marked increased PPARc and DKK-1 mRNA expression. When treated the Ad-in rMSC with Sal B, the PPARc and DKK-1
mRNA expression decreased obviously. Sal A had similar effects to Sal B.
doi:10.1371/journal.pone.0034647.g013
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receptor c; VEGF: vascular endothelial growth factor; Black: effect
of glococorticoid; Red: effect of Salvianolic acid B; q: increase;
Q: decrease).
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